Hospital Fun
Release time:
2021-12-23
This year # In late February, I was admitted to the hospital because my blood pressure was too high. Although sick people worry, but also met some interesting.
The day after hospitalization, the attending doctor arranged for me to have an MRI examination. After reporting to the examination room, he was led into a room with extremely low room temperature. The doctor asked me to take off my mobile phone, watch, keys, coins and other metal objects and put them aside. Then he handed me two cotton balls to plug my ears and lie on a bed. At this time, I was covered with a blanket, my head was put on a big glass cover, and I was an astronaut.
After a while, I was pushed into a space capsule-like machine. I didn't know what I was going to face, and my heart was full of fear and excitement. Suddenly, there was a huge rhythmic beating around me. If I hadn't stopped my ears with cotton beforehand, I would have been almost stunned by this beating. The sound lasted for more than a minute, and it felt almost unbearable, making people almost collapse. That's when I figured out a way to sing! Gently humming the track "Under the Bright Sun" from last month's chorus. Don't you say, this song matches the rhythm of the beating sound quite well, humming and humming, feeling much better. However, after the song was hummed once, the huge beating continued. I had to start the second time. When will this frightening sound end?
After a while, the beating finally ended. I thought I could finally leave here, but then there was a shaking of my whole body, which almost made me spit it out. I have another "Spiritual Victory " , and think of it as Michael · Jackson's quick dance. It doesn't feel that bad. In a short period of 15 minutes, I seem to have experienced 50 minutes.
After the examination, I took my belongings and came out of the examination room. I was embarrassed to find that the belt buckle was out of order and my pants could not be buckled. I hurried to the supermarket near the hospital to buy a belt with my pants. The supermarket owner saw me in this situation, smiled and asked me if I was wearing a belt when I was doing MRI. Only then did I suddenly realize that it was the magnetic resonance that broke the belt buckle. (Hong Zhiwei)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31